N/A Completed N=100 Randomized Treatment

Efficacy of the Nanodropper Device on Pupillary Dilation

Dilation

Source: ClinicalTrials.gov NCT05274321 ↗

Enrolled (actual)

100

Serious AEs

0.0%

Results posted

Sep 2023

Primary outcomePrimary: Spherical Equivalent — -2.62; -2.28; -0.86; -0.55 Diopters — p=0.22

Summary

Prescription eye drop bottles elute drops that exceed the capacity of the human eye by five times. This study describes performing in clinic dilation using a novel solution for combating medical waste with Nanodropper, an eye drop bottle adapter that creates smaller eye drops.

Outcome Measures

Outcome	Result	p-value
PRIMARY Spherical Equivalent	-2.62; -2.28; -0.86; -0.55; 1.76; 1.73	0.22
PRIMARY Maximum Pupil Diameter	5.95; 6.01; 7.91; 7.81; 1.95; 1.77	0.02 sig
PRIMARY Constriction Percentage	30.44; 31.07; 5.67; 6.26; -24.76; -24.81	0.03 sig
SECONDARY Change in Intraocular Pressure	17.36; 18.13; 18.42; 17.96; 1.06; -0.17	0.25

Eligibility Criteria

Inclusion Criteria

Participants under the age of 18 years old

Exclusion Criteria

Participants 18 years and older
Pupillary or anterior segment abnormality
Participants with pre-existing health conditions that would prevent pupillary dilation.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05274321). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.